Wednesday, Roche Holdings AG (OTC:RHHBY) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity. CT-996 is an investigational, once-daily oral small molecule GLP-1 receptor agonist being developed for type 2 diabetes and obesity. Also Read: Roche’s New Immunotherapy Fails To Show Benefit Over Merck’s Blockbuster Keytruda In Lung Cancer Patients. The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in ...